Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Short LLY ETF

8.57
0.0000
Volume:- -
Turnover:- -
Market Cap:1.54M
PE:- -
High:8.57
Open:8.57
Low:8.57
Close:8.57
52wk High:17.92
52wk Low:7.63
Shares:180.00K
Float Shares:180.00K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly - Aims to Treat Equal Number of Patients in Lmics and High-Income Countries by 2040

THOMSON REUTERS
·
Sep 28

JPMorgan Adjusts Price Target on Eli Lilly to $1,500 From $1,400, Maintains Overweight Rating

MT Newswires Live
·
Sep 28

Eli Lilly's Olumiant Gets FDA Approval for Severe Alopecia Areata in Adolescents

MT Newswires Live
·
Sep 28

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

TIPRANKS
·
Sep 28

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Sep 25

Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis

TradingKey
·
Sep 24

Lilly's Next-Gen Obesity Efforts Could Tip Scales Further in Its Favor, Citi Says

Reuters
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT

Reuters
·
Sep 23

Eli Lilly Price Target Maintained with a $1250.00/Share by TD Cowen

Dow Jones
·
Sep 22